Structures cytology interpretation with Bethesda system for cervical and other body site classifications. Use when reading cytology, applying Bethesda classifications, or documenting cytologic findings.
Structures cytology interpretation with Bethesda system for cervical and other body site classifications.
Why This Skill Exists
Cytology interpretation directly governs cancer screening, triage, and management pathways for millions of patients annually. The Bethesda System for Reporting Cervical Cytology (TBS), now in its third edition, is the universal standard for Pap test reporting and links each diagnostic category to specific ASCCP management guidelines. Errors in cytology — false negatives in cervical screening, missed malignant cells in effusions, or inadequate specimen assessments — have well-documented consequences including delayed cancer diagnosis and medicolegal exposure.
CLIA regulations (42 CFR 493.1257) impose specific workload limits for cytotechnologists (no more than 100 slides per 24 hours), require 10% random rescreening, mandate cyto-histo correlation, and demand annual statistical review. CAP accreditation adds checklist requirements for gynecologic and non-gynecologic cytology (CYP checklist series). This skill ensures that every cytology interpretation follows TBS and CAP standards with defensible documentation.
Checkpoint A: Pre-Draft Intake (Mandatory)
相关技能
Specimen type — Cervical (Pap), body fluid, FNA, urine, bronchial wash, or other? Default: cervical Pap.
Body fluids: Assess cellularity relative to clinical context; a paucicellular transudative effusion may be adequate
FNA: At least 6 groups of 10+ benign follicular cells for thyroid (Bethesda System for Reporting Thyroid Cytopathology)
Urine: No absolute cell count; assess by clinical context, but note if acellular or degenerated
Document any quality indicators: air-drying artifact, lubricant contamination, scant transformation zone component (TZC/EC), or obscuring elements.
Step 2: Systematic Screening and Interpretation
Cervical Cytology — The Bethesda System (TBS 3rd Edition)
Apply TBS categories in hierarchical order:
NILM (Negative for Intraepithelial Lesion or Malignancy): Normal or reactive/reparative changes, organisms (Trichomonas, Candida, bacterial vaginosis shift, Actinomyces, HSV).
Epithelial Cell Abnormalities — Squamous:
ASC-US: Atypical squamous cells of undetermined significance
Adenocarcinoma: Endocervical, endometrial, extrauterine, or NOS
Non-Gynecologic Cytology
Body fluids: Negative for malignancy, atypical cells (favor reactive vs. favor neoplastic), suspicious for malignancy, positive for malignancy. Classify cell type.
Thyroid FNA: Apply Bethesda System for Reporting Thyroid Cytopathology (BSRTC) categories I-VI.
Pancreaticobiliary FNA: Apply Papanicolaou Society guidelines.
Urine: Apply Paris System for Reporting Urinary Cytology (TPSRUC) categories.
Step 3: Ancillary Studies and Correlation
HPV reflex testing: For ASC-US, reflexing to hrHPV is standard per ASCCP 2019 guidelines. Document result and management implication.
Immunocytochemistry: p16/Ki-67 dual stain for triage of HPV-positive/ASC-US or LSIL. Calretinin, BerEP4, MOC-31, D2-40 for mesothelial vs. adenocarcinoma in effusions.
Cell block evaluation: If cell block was prepared, correlate with liquid-based or smear findings. Apply IHC panel for tumor typing on cell block material.
Molecular testing: HPV genotyping (16, 18 vs. other hrHPV), UroVysion FISH for urine cytology, flow cytometry on body fluids with suspected lymphoma.
Step 4: Cyto-Histo Correlation
Per CLIA 42 CFR 493.1274 and CAP CYP.05900:
Correlate all positive or atypical cervical cytology with subsequent biopsy within 6 months.
Document correlation as: concordant, minor discordance (one grade), or major discordance (two or more grades).
Major discordances require review by cytopathologist and may trigger slide re-review.
Maintain a cyto-histo correlation log with quarterly statistical review.
For non-gyn cytology, correlate FNA diagnoses with surgical pathology when excision follows.
Step 5: Report Assembly and Sign-Out
Construct the final report per TBS format:
Specimen type and preparation: State method (ThinPrep, SurePath, conventional, FNA).
Adequacy statement: Must appear as the first diagnostic line.
General categorization: NILM or Epithelial Cell Abnormality.
Interpretation/Result: Specific TBS category with qualifiers.
Educational notes/suggestions: Include ASCCP management recommendation when applicable (e.g., "Per ASCCP 2019 guidelines, HPV 16/18 positive ASC-US warrants direct referral to colposcopy").
Comment: Address any discordance, limitations, or recommendations.
Checkpoint B: Post-Draft Alignment (Mandatory)
Is the adequacy statement the first element of the interpretation and does it meet TBS criteria?
Does the TBS category exactly match the standardized terminology (no hybrid or non-standard terms)?
Is the HPV co-test or reflex result documented and correlated with the cytologic interpretation?
For non-gyn specimens, is the appropriate reporting system used (Paris, BSRTC, Papanicolaou Society)?
Are cyto-histo correlation requirements met for any prior abnormal results?
Quality Audit
Specimen adequacy evaluated and documented as first diagnostic element
TBS terminology used verbatim for cervical cytology categories
HPV co-test or reflex result integrated into interpretation
ASCCP management recommendation included where applicable
Non-gynecologic specimens classified per appropriate system (Paris, BSRTC)
Cell block findings correlated with cytology preparation
FNA adequacy assessed per site-specific criteria (e.g., 6 groups for thyroid)
Cyto-histo correlation documented for cases with prior tissue diagnosis
Workload recorded per CLIA 42 CFR 493.1257 (max 100 slides/24 hours)
10% rescreening of negative cases documented
Quarterly statistical review completed with sensitivity/specificity metrics
Report turnaround within institutional and CAP benchmarks
Guidelines
Always report specimen adequacy as the first element; never omit it even for positive cases
Use exact TBS 3rd edition terminology for cervical cytology; do not modify or abbreviate diagnostic categories
For thyroid FNA, apply Bethesda System for Reporting Thyroid Cytopathology with implied risk of malignancy for each category
Include ASCCP management recommendations as educational notes when the diagnosis triggers a specific guideline action
Maintain strict CLIA workload limits and document daily case counts
Correlate all abnormal cervical cytology with tissue follow-up within 6 months; escalate unresolved discordances
For body fluid cytology, always state whether findings are negative, suspicious, or positive for malignancy, and classify the malignant cell type when positive
Never downgrade a cytologic interpretation based solely on clinical expectation; document morphologic basis for every diagnosis